Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 332 for:    DONEPEZIL

DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02711683
Recruitment Status : Recruiting
First Posted : March 17, 2016
Last Update Posted : January 29, 2019
Sponsor:
Information provided by (Responsible Party):
First Affiliated Hospital Xi'an Jiaotong University

Brief Summary:

Alzheimer's disease (AD) is the commonest cause of dementia. There is no effective treatment to cure the disease. Cholinesterase inhibitors, such as donepezil, are widely recommended to patients with mild to moderate AD. But the cognitive function of most of the patients using donepezil gradually aggravate, with Mini-Mental State Examination(MMSE) score falling by 2 points per year on average, and donepezil cannot effectively delay AD progress.

DL-3-n-butylphthalide(NBP) is a synthetic chiral compound containing L- and D-isomers of butylphthalide. It is developed from L-3-n-butylphthalide, which was initially isolated as a pure component from seeds of Apium graveolens in 1978 by researchers of Institute of Medicine of Chinese Academy of Medical Sciences. Studies in the past several decades have demonstrated that NBP is effective in alleviating oxidative damage and mitochondria dysfunction, improving microcirculation. NBP was approved by the State Food and Drug Administration of China (SFDA) as a therapeutic drug for treatment of ischemic stroke in 2005 Not only for ischemic stroke, NBP has been reported to increase the expression of N-methyl-D-aspartate subtype glutamate receptor 2B(NR2B) and synaptophysin in hippocampus of aged rats after chronic cerebral hypoperfusion and increasing brain acetylcholine level, which are important processes involved in learning and memory. It could alleviate the learning and memory deficits induced by cerebral ischemia in rats. A multicentre, randomized, double-blind, placebo-controlled trial conducted by Professor Jia investigated that NBP was effective for improving cognitive and global functioning in patients with subcortical vascular cognitive impairment without dementia and exhibited good safety over the 6-month treatment period. The pathogenesis of AD involved mitochondria dysfunction and microcirculation dysfunction, which are the action targets of NBP. Investigators observed that MMSE score lowering slowly when using NBP treatment in patients with mild to moderate AD already receiving donepezil. But investigators lack of system evaluation and follow-up. Hence, investigators hypothesized that NBP may have therapeutic efficacy for patients with AD and designed the present study.


Condition or disease Intervention/treatment
Alzheimer's Disease Drug: DL-3-n-butylphthalide Drug: Donepezil

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil : A Multi Center, Prospective Cohort Stud
Actual Study Start Date : March 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : March 2020


Group/Cohort Intervention/treatment
DL-3-n-butylphthalide group
using DL-3-n-butylphthalide treatment in patients with mild to moderate AD already receiving donepezil
Drug: DL-3-n-butylphthalide
the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Other Name: NBP

Drug: Donepezil
the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Other Name: Aricept

donepezil group
only using donepezil treatment in patients with mild to moderate AD
Drug: Donepezil
the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Other Name: Aricept




Primary Outcome Measures :
  1. Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) [ Time Frame: Baseline, 48 weeks ]
    Primary efficacy parameter is the baseline- to-endpoint score change on ADAS-cog. The participants will be followed up every 12 weeks. There is five times interviews totally. The investigators compare the the baseline- to-endpoint score change on ADAS-cog at last.


Secondary Outcome Measures :
  1. Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) [ Time Frame: Baseline, 48 weeks ]
    secondary efficacy parameter is the endpoint score on CIBIC-plus

  2. Alzheimer's Disease Cooperative Study-Activities of Daily Living(ADCS-ADL) [ Time Frame: Baseline, 48 weeks ]
    Secondary efficacy parameter is the baseline-to-endpoint score change on the ADCS-ADL.The participants will be followed up every 12 weeks. There is five times interviews totally. The investigators compare the the baseline- to-endpoint score change on ADCS-ADL at last.

  3. Neuropsychiatric Inventory(NPI) [ Time Frame: Baseline, 48 weeks ]
    Additional parameter included the baseline-to-endpoint score changes on the NPI.The participants will be followed up every 12 weeks. There is five times interviews totally. The investigators compare the the baseline- to-endpoint score change on NPI at last.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
Criteria

Inclusion Criteria:

  • literate Chinese, aged 50-85 years, with a consistent caregiver who accompanied the subjects at least 4 days a week,2 hours a day;
  • complaint and/or informant report of cognitive impairment involving memory and/or other cognitive domains lasting for at least 12 months; and progressing gradually.
  • diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria;
  • a mini-mental state examination (MMSE) score ≥11 and ≤22 (primary school) or ≥11 and ≤26 (junior school or above) ;
  • Hachinski ischemia scale score ≤4;
  • All patients meeting the clinical criteria underwent brain magnetic resonance imaging (MRI) scan including hippocampal assessment at screening. The MRI entry criteria are as follows: the number of cerebral infarcts (≥20 mm in diameter)less than 2, without infarcts in thalamus, hippocampal or entorhinal cortex, the medial temporal lobe atrophy visual rating scale (MTA) score more than 2 degree.
  • absent of neurological sign;
  • having used donepezil more than 3 months and remained relatively stable;
  • sign the informed consent.

Exclusion Criteria:

  • severe white matter lesion(WML)(score ≥3 according to the Fazekas rating scale), the number of cerebral infarcts (≥20 mm in diameter)more than 2, with infarcts in the important sites, such as thalamus, hippocampal or entorhinal cortex;
  • dementia due to other causes, such as vascular dementia, infection of central nervous system,dementia with Lewy body(DLB),etc
  • suffered from other neurological disease, such as stroke, Parkinson's disease, epilepsy;
  • suffered from mental disorders, such as schizophrenia,bipolar disorder,severe depression, delirium;
  • suffered from unstable or severe disorders of heart, lung, liver, kidney and blood system;
  • Severe impairment of vision and hearing;
  • Using other cholinesterase inhibitors or memantine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02711683


Contacts
Layout table for location contacts
Contact: Jin Wang 0086-13572208524 drwangjin@163.com

Locations
Layout table for location information
China, Shaanxi
First Affiliated Hospital of Xi'an Jiaotong University Recruiting
Xi'an, Shaanxi, China, 710061
Contact: Jin Wang    0086-13572208524    drwangjin@163.com   
Sponsors and Collaborators
First Affiliated Hospital Xi'an Jiaotong University
Investigators
Layout table for investigator information
Study Director: qiu-min Qu First Affiliated Hospital Xi'an Jiaotong University

Layout table for additonal information
Responsible Party: First Affiliated Hospital Xi'an Jiaotong University
ClinicalTrials.gov Identifier: NCT02711683     History of Changes
Other Study ID Numbers: XJTU1AF-CRF-2015-027
First Posted: March 17, 2016    Key Record Dates
Last Update Posted: January 29, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Donepezil
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
3-n-butylphthalide
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents
Platelet Aggregation Inhibitors
Neuroprotective Agents
Protective Agents